The estimated Net Worth of Thomas Richard Kassberg is at least $22.7 Million dollars as of 11 March 2024. Mr. Kassberg owns over 11,509 units of Ultragenyx Pharmaceutical stock worth over $14,241,520 and over the last 11 years he sold RARE stock worth over $5,970,524. In addition, he makes $2,456,500 as Chief Business Officer und Executive Vice President at Ultragenyx Pharmaceutical.
Thomas has made over 25 trades of the Ultragenyx Pharmaceutical stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 11,509 units of RARE stock worth $574,644 on 11 March 2024.
The largest trade he's ever made was exercising 109,734 units of Ultragenyx Pharmaceutical stock on 30 September 2021 worth over $34,018. On average, Thomas trades about 5,186 units every 79 days since 2014. As of 11 March 2024 he still owns at least 252,823 units of Ultragenyx Pharmaceutical stock.
You can see the complete history of Mr. Kassberg stock trades at the bottom of the page.
Thomas Kassberg serves as Chief Business Officer, Executive Vice President of the Company. Mr. Kassberg worked as Vice President of Business Development at Corium International, Inc., a biotechnology company, from July 2010 until October 2011. Prior to his work at Corium International, Inc., Mr. Kassberg worked as an independent consultant in corporate development and business strategy and consulted with a number of companies from March 2009 to June 2010, including Corium International, Inc., a biopharmaceutical company, and Rib-X Pharmaceuticals, Inc., a pharmaceutical company focused on the development of novel antibiotics. Before becoming a consultant, Mr. Kassberg worked at Proteolix, Inc., a biotechnology company subsequently acquired by Onyx Pharmaceuticals, from January 2008 until February 2009, where he served as Senior Vice President of Corporate Development. Mr. Kassberg holds a B.A. in Business Administration from Gustavus Adolphus College and an M.B.A. from Northwestern University.
As the Chief Business Officer und Executive Vice President of Ultragenyx Pharmaceutical, the total compensation of Thomas Kassberg at Ultragenyx Pharmaceutical is $2,456,500. There are 4 executives at Ultragenyx Pharmaceutical getting paid more, with Emil Kakkis having the highest compensation of $6,586,480.
Thomas Kassberg is 59, he's been the Chief Business Officer und Executive Vice President of Ultragenyx Pharmaceutical since 2016. There are 7 older and 16 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.
Thomas's mailing address filed with the SEC is 60 Leveroni Ct, Novato, CA 94949, USA.
Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr und Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.
ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d
Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: